SCHEMBL4334524

SCHEMBL4334524

CC(c1ccc(Cl)cc1)C(CC(C(=O)NO)c1ncco1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FFAR2 O15552 4/20 0.43
PRCP P42785 5/20 0.38
CNR1 P21554 4/20 0.37
CNR2 P34972 3/20 0.37
MAPK14 Q16539 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
MMP7 P09237 1/20 0.35
S1PR1 P21453 1/20 0.34
S1PR3 Q99500 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4328657 0.94 MMP1 (0.38) HDAC4HDAC7HDAC5MMP1MMP2
SCHEMBL4327041 0.90 CTSA (0.39) MAPK14HDAC4HDAC7HDAC5
SCHEMBL4327900 0.89 FFAR2 (0.41) FFAR2PRCPCNR1CNR2MAPK14
SCHEMBL4340135 0.88 CTSA (0.40) MEN1KMT2AMMP1MMP2MMP3
SCHEMBL4327095 0.86 CTSA (0.39) FFAR2MMP1MMP2MMP3MMP7
SCHEMBL4339970 0.86 MMP1 (0.38) FFAR2HDAC4HDAC7HDAC5MMP1
SCHEMBL4325351 0.85 HDAC3 (0.39) HDAC4HDAC7HDAC5
SCHEMBL4337653 0.85 GPR119 (0.41) FFAR2PRCPCNR1CNR2MAPK14
SCHEMBL4334429 0.84 MMP1 (0.38) HDAC4HDAC7HDAC5MMP1MMP2
SCHEMBL4329478 0.83 CTSA (0.39) MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7521563-B2 Hydroxamic acid derivative and medicine containing the same as active ingredient SHIZUOKA COFFEIN CO., LTD. (JP) 2009-04-21 US claimed
US-20070208065-A1 Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient SHIZUOKA COFFEIN CO., LTD. (JP) 2007-09-06 US claimed
EP-1787986-A1 HYDROXAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT SHIZUOKA COFFEIN CO., LTD. (JP) 2007-05-23 EP claimed
US-7521563-B2 Hydroxamic acid derivative and medicine containing the same as active ingredient SHIZUOKA COFFEIN CO., LTD. (JP) 2009-04-21 US disclosed
US-20070208065-A1 Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient SHIZUOKA COFFEIN CO., LTD. (JP) 2007-09-06 US disclosed
EP-1787986-A1 HYDROXAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT SHIZUOKA COFFEIN CO., LTD. (JP) 2007-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208065-A1 Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient IL6, IL1A, TNF FFAR2 1603/4885PRCP 3113/4885CNR1 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.